Discontinuity and failures of therapy with bisphosphonates: Joint assessment of predictors with multi-state models

Pharmacoepidemiology and Drug Safety

Volumn 17, Issue 3, 2008, Pages 260-269

  Zambon, Antonella ^a   Baio, Gianluca ^a,b   Mazzaglia, Giampiero ^c,d   Merlino, Luta ^e   Corrao, Giovanni ^a  

^a UNIVERSITY OF MILANO BICOCCA   (Italy)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c Regional Health Agency of Tuscany   (Italy)

^d Italian College of General Practitioners   (Italy)

^e Operative Unit of Territorial Health Services   (Italy)

Author keywords

Bisphosphonates; Bone fracture; Multi state model; Osteoporosis; Prospective cohort study; Record linkage; Treatment discontinuation

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CORTICOSTEROID; RALOXIFENE; RISEDRONIC ACID; SEX HORMONE;

ADULT; AGE; AGED; ARTICLE; COHORT ANALYSIS; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; FRAGILITY FRACTURE; GASTROINTESTINAL TOXICITY; HUMAN; ITALY; MAJOR CLINICAL STUDY; OBSERVATIONAL STUDY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PHARMACOEPIDEMIOLOGY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; RETREATMENT; RISK REDUCTION; STATISTICAL MODEL;

AGE FACTORS; AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY CONSERVATION AGENTS; COHORT STUDIES; DIPHOSPHONATES; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORECASTING; FRACTURES, BONE; GLUCOCORTICOIDS; HUMANS; ITALY; MIDDLE AGED; OSTEOPOROSIS; PATIENT COMPLIANCE; PHARMACOEPIDEMIOLOGY; PROSPECTIVE STUDIES; TREATMENT FAILURE;

EID: 40949126534     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1530     Document Type: Article

References (59)

1. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. JAMA 2001; 285: 785-795.
2. Cummings SR, Melton LJ. Epidemiology and outcomes of osteoporotic fractures. Lancet 2002; 359: 1761-1767.
3. Kai MC, Anderson M, Lau EM. Exercise interventions: defusing the world's osteoporosis time bomb. Bull World Health Organ 2003; 81: 827-830.
4. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med 1995; 333: 1437-1443.
5. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996; 348: 1535-1541.
6. Cummings SR. Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA 1998; 280: 2077-2082.
7. Pols HA, Felsenberg D, Hanley DA, et al. Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int 1999; 9: 461-468.
8. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999; 282: 1344-1352.
9. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int 2000; 11: 83-91.
10. McClung MR, Geusens P, Miller PD, et al. Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med 2001; 344: 333-340.
11. Dowd R, Recker RR, Heany RP. Study subjects and ordinary patients. Osteoporos Int 2000; 11: 533-536.
12. Emkey RD, Ettinger M. Improving compliance and persistence with bisphosphonate therapy for osteoporosis. Am J Med 2006; 119: 18S-24S.
13. Cortet B, Bénichou O. Adherence, persistence, concordance: do we provide optimal management to our patients with osteoporosis? Joint Bone Spine 2006; 73: e1-e7.
14. Turbi C, Herrero-Beaumont G, Acebes JC, et al. Compliance and satisfaction with raloxifene versus alendronate for the treatment of postmenopausal osteoporosis in clinical practice: an open-label, prospective, nonrandomized, observational study. Clin Ther 2004; 26: 245-256.
15. McCombs JS, Thiebaud P, McLaughlin-Miley C, Shi J. Compliance with drug therapies for the treatment and prevention of osteoporosis. Maturitas 2004; 48: 271-287.
16. Yood RA, Emani S, Reed JI, Lewis BE, Charpentier M, Lydick E. Compliance with pharmacologic therapy for osteoporosis. Osteoporos Int 2003; 14: 965-968.
17. Solomon DH, Avorn J, Katz JN, et al. Compliance with osteoporosis medication. Arch Intern Med 2005; 165: 2414-2419.
18. Boccuzzi SJ, Foltz SH, Omar MA, Kahler KH, Guttierez B. Adherence and persistence associated with pharmacology treatment of osteoporosis. Osteoporos Int 2005; 16: S24.
19. Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. Curr Med Res Opin 2005; 21: 1453-1460.
20. Lo JC, Pressman AR, Omar MA, Ettinger B. Persistence with weekly alendronate therapy among postmenopausal women. Osteoporos Int 2006; 17: 922-928.
21. Brankin E, Walker M, Lynch N, Aspray T, Lis Y, Cowell W. The impact of dosing frequency on compliance and persistence with bisphosphonates among postmenopausal women in the UK: evidence from three databases. Curr Med Res Opin 2006; 22: 1249-1256.
22. Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. Mayo Clin Proc 2005; 80: 856-861.
23. Carr AJ, Thompson PW, Cooper C. Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey. Osteoporos Int 2006; 17: 1638-1644.
24. Carnevale V, Nieddu L, Romagnoli E, et al. Osteoporosis intervention in ambulatory patients with previous hip fracture: a multicentric, nationwide Italian survey. Osteoporos Int 2006; 17: 478-483.
25. Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc 2006; 81: 1013-1022.
26. van den Boogaard CH, Breekveldt-Postma NS, Borggreve SE, Goettsch WG, Herings RM. Persistent bisphosphonate use and the risk of osteoporotic fractures in clinical practice: a database analysis study. Curr Med Res Opin 2006; 22: 1757-1764.
27. Weycker D, Macarios D, Edelsberg J, Oster G. Compliance with drug therapy for postmenopausal osteoporosis. Osteoporos Int 2006; 17: 1645-1652.
28. Downey TW, Foltz SH, Boccuzzi SJ, Omar MA, Kahler KH. Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 2006; 99: 570-575.
29. Bartl R, Gotte S, Hadji P, Hammerschmidt T. Adherence with daily and weekly administration of oral bisphosphonates for osteoporosis treatment. Dtsch Med Wochenschr 2006; 131: 1257-1262.
30. Caro JJ, Ishak KJ, Huybrechts KF, Raggio G, Naujoks C. The impact of compliance with osteoporosis therapy on fracture rates in actual practice. Osteoporos Int 2004; 15: 1003-1008.
31. Mullins CD, Ohsfeldt RL. Modelling the annual costs of postmenopausal prevention therapy: raloxifene, alendronate, or estrogen-progestin therapy. J Manag Care Pharm 2003; 9: 150-158.
32. de Groen PC, Lubbe DF, Hirsch LJ, et al. Esophagitis associated with the use of alendronate. N Engl J Med 1996; 335: 1016-1021.
33. Lanza FL, Hunt RH, Thomson AB, Provenza JM, Blank MA. Endoscopic comparison of esophageal and gastroduodenal effects of risedronate and alendronate in postmenopausal women. Gastroenterology 2000; 119: 631-638.
34. Marubini E, Valsecchi MG. Analysing survival data from clinical trials and observational studies. John Wiley & Sons: New York, 1995.
35. Andersen PK, Keiding N. Multi-state models for event history analysis. Stat Methods Med Res 2002; 11: 91-115.
36. Putter H, van der Hage J, de Bock GH, Elgalta R, van de Velde CJH. Estimation and prediction in a multi-state model for breast cancer. Biometrical J 2006; 3: 366-380.
37. Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. Stat Med 2007; 26: 2389-2430.
38. Therneau TM, Grambsch PM. Modeling Survival Data: Extending the Cox Model. Statistics for Biology and Health. Springer: New York, 2001.
39. Lin DY, Wie LJ. The robust inference for the Cox proporional hazards model. J Am Stat Assoc 1989; 84: 1074-1079.
40. SAS Institute Inc. Release 8.1 enhancements to SAS/STAT software. Available at http://support.sas.com/rnd/app/da/new/dastat81.html.
41. Ettinger MP, Gallagher R, MacCosbe PE. Medication persistence with weekly versus daily doses of orally administered bisphosphonates. Endocr Pract 2006; 12: 522-528.
42. Watts NB, Worley K, Solis A, Doyle J, Sheer R. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database. J Manag Care Pharm 2004; 10: 142-151.
43. Bonnick S, Saag KG, Kiel DP, et al. Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 2006; 91: 2631-2637.
44. Gold DT, Alexander IM, Ettinger MP. How can osteoporosis patients benefit more from their therapy? Adherence issues with bisphosphonate therapy. Ann Pharmacother 2006; 40: 1143-1150.
45. Sambrook P. Compliance with treatment in osteoporosis patients - an ongoing problem. Aust Fam Physician 2006; 35: 135-137.
46. Cooper A, Drake J, Brankin E; the PERSIST Investigators. Treatment persistence with once-monthly ibandronate and patient support vs. once-weekly alendronate: results from the PERSIST study. Int J Clin Pract 2006; 60: 896-905.
47. Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. Am J Med 2006; 119: S12-S17.
48. Miller PD. Optimizing the management of postmenopausal osteoporosis with bisphosphonates: the emerging role of intermittent therapy. Clin Ther 2005; 27: 361-376.
49. Pyon EY. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen. Clin Ther 2006; 28: 475-490.
50. Chesnut III, Skag CH, Christiansen A, et al.; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004; 19: 1241-1249.
51. Chesnut CH. Treating osteoporosis with bisphosphonates and addressing adherence: a review of oral ibandronate. Drugs 2006; 66: 1351-1359.
52. Dempster DW, Bolognese MA. Ibandronate: the evolution of a once-a-month oral therapy for postmenopausal osteoporosis. J Clin Densitom 2006; 9: 58-65.
53. Kishimoto H, Fukunaga M, Kushida K, et al.; Risedronate Phase III Research Group. Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen. J Bone Miner Metab 2006; 24: 405-413.
54. Reginster JY. Adherence and persistence: impact on outcomes and health care resources. Bone 2006; 38: S18-S21.
55. Bobba RS, Beattie K, Parkinson B, Kumbhare D, Adachi JD. Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease. Drug Saf 2006; 29: 1133-1152.
56. Cattaruzzi C, Troncon MG, Agostinis L, Garcia Rodriguez LA. Positive predictive value of ICD-9th codes for upper gastrointestinal bleeding and perforation in the Sistema Informativo Regionale database. J Clin Epidemiol 1999; 52: 499-502.
57. Leufkens HG, Urquhart J. Variability in patterns of drug usage. J Pharm Pharmacol 1994; 46: 433-437.
58. McMahon AD, Evans JMM, McGilchrist MM, McDevitt DG, MacDonald TM. Drug exposure risk windows and unexposed comparator groups for cohort studies in pharmacoepidemiology. Pharmacoepidemiol Drug Saf 1998; 7: 275-280.
59. Evans JMM, MacDonalds M. Misclassification and selection bias in case-control studies using an automated database. Pharmacoepidemiol Drug Saf 1997; 6: 313-318.